A wholly-owned venture arm subsidiary of one of the largest health insurers makes strategic investments in healthcare-related innovations that will improve the quality of care and enhance the overall healthcare experience for consumers and providers. 3 important considerations are strategic value, financial return, and improvement in health outcomes. The firm typically participates in Series B or post-Series A bridge rounds. The firm entertains domestic and international opportunities.

The firm invests broadly across healthcare. Recent investments include a lung cancer diagnostics company, a specialty pharmacy company that simplifies medication management, and a behavioral health care management company. The firm expects companies to be past the proof-of-concept stage with demonstration of some traction.

The firm has no specific requirements and can work with all kinds of management teams. The firm is open to both leading and co-investing in financing rounds. The firm may take a board seat when applicable.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment arm of a large, Czech Republic-based financial group that manages 10 sub-funds that total to $400M AUM, has a $22M fund through which the firm actively invests in early-stage life-science companies. The firm prefers to act as the first institutional investor – i.e. it deploys around $250 to $350,000 as initial investment and then provides follow-on investments for companies that achieve a number of milestones. The firm will consider opportunities globally, but mainly focuses its activities in North America and Europe.

The fund is sector agnostic and will consider all innovative technologies within the areas of therapeutics, medical devices, diagnostics, and healthcare IT. About 1/3 of the fund is dedicated to digital health technologies with special interest in the area of mental health. While the fund is mostly indication agnostic, it tends to avoid the over-crowded indications such as oncology/immune-oncology.

The firm is an active investor and takes a dedicated role in its portfolio of companies, providing them with resources and expertise to support company growth. The firm seeks to work with experienced management teams that are working on technology with strong market potential. The firm prefers to act as the lead investor but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed-stage venture capital fund that seeks to invest in Ontario-based companies operating in the cleantech, information and communication technology, life science and healthcare sectors. The firm is based out of Toronto, Canada and has been investing for over 10 years. The fund is sector-agnostic and invests in several verticals including but not limited to IT, healthcare, and cleantech. The fund makes investments up to $500K in Ontario-based startups, and typically targets 15 deals per year. The fund will invest with VCs and other institutional investors.

The fund is a generalist fund, but within the healthcare space, the focus is on healthcare IT and digital health companies whose core technology is software, whether it be enterprise solutions or more consumer-facing or point of care technologies. Traditional medical devices, biopharma/therapeutics and other life science platform technologies will be also be considered.

The firm requires the company be legally company incorporated and likes to see a formal management structure in place by the time of closing an investment. It’s not necessary that the company have revenues, but the company must have a clear understanding of their path to market and an execution strategy in place that will allow them to move faster than competitors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Canada-based firm founded in 2010 consists of a team of entrepreneurs seeking to invest in small-to-mid sized healthcare & pharmaceutical companies. The firm is open to investing in private companies at all stages from seed through growth and expansion. The firm can act as a co-investor or lead, and additionally can leverage distribution networks and partnerships across 4 continents. Typical allocations are < €25 M structured as equity, and may come from a combination of the partners' personal funds, a family office whose wealth is managed by the firm, or the firm's own fund. Portfolio companies focus on specialty pharmaceuticals, biotechnology, medical devices, & ancillary health services. The firm will invest in English-speaking markets.

The firm’s specialty area is in generic pharmaceutical manufacturing and distribution, and manufacturing and distribution of specialty medical devices. Urology and urogynecology devices, injectable medications, cardiovascular medications, dental devices, vaccines, oncology therapeutics, diagnostics, and surgical simulators are reflected in portfolio companies. The firm is open to reviewing technology in all stages of development. Devices that fit well in the focus and distribution regions of portfolio companies are of particular interest.

The firm looks for strong & accomplished management teams and above all, values innovation, transparency, integrity, execution, and fun. The firm may or may not seek a board seat depending on the structure of the allocation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with offices in Spain invests in early-stage companies in the life science and technology sectors. The firm makes investments of EUR 2-6 million in seed and early stage financing rounds. The firm makes both equity and venture debt investments. The firm focuses on investment opportunities in Spain but will also consider deals elsewhere in Europe or in North America.

In the life sciences, the firm focuses on therapeutics and also invests in diagnostics, medical devices and healthcare IT. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. In diagnostics, the firm focuses on opportunities with an identified biomarker or a completed retrospective study. In medical devices and healthcare IT, the firm only invests in companies that are very close to commercialization or already generating revenues. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with no more than EUR 6 million in further private investment.
In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the largest Canadian-based venture capital firms focused exclusively on the life sciences industry is making seed and venture investments from its third fund of $125M, and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.

The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.

The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Boston, San Francisco and Toronto, Ontario invests in several verticals including enterprise software, media and technology, health and life sciences, virtual reality, industrial & business services and blockchain solutions. The fund makes initial investments in the range of $250K – $1M in the form of straight equity or convertible notes and typically targets seed and series A rounds. The firm only leads or co-leads rounds that they can capture a meaningful stake in the company and chunk of the round with $1M. The fund looks to be very active in their investments and add value to portfolio companies through ongoing support and advice as well as leveraging a broad business network. The firm is focused on companies based in the U.S. and Canada and looks to do 10-20 deals per year.

In the healthcare space, the firm is primarily interested in the healthcare IT/digital health, medtech and diagnostics space. The fund is not interested in traditional medical devices and diagnostics that require FDA approval, but rather devices and diagnostics with both a hardware and software component which do not require a traditional regulatory pathway. The fund is most interested in point-of-care and consumer facing technologies as well as platform technologies that help bolster and make the drug discovery/research process more efficient and accurate.

The firm is looking for companies with some type of traction, not necessarily revenue but at least an LOI or pilot in place. The fund will work with novice entrepreneurs, but the founder(s) should at least have deep technical expertise in the area they are pursuing. The firm looks for a board seat as well as pro rata and information rights along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.